ArticleMicrobiology spectrum2022
Clinical and Microbiological Characteristics of Mycobacterium kansasii Pulmonary Infections in China.
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Global trends in the proportion of macrolide-resistant Mycobacterium Species: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Prevalence ofFrontiers in microbiology · 2024Pooled it
- Rare primary small intestinal infection: a case report of Mycobacterium kansasii enteropathy in an immunocompetent patient and literature review.BMC infectious diseases · 2026Review
- Shenling Baizhu Powder Alleviated Lung Damage and Enhanced Immunoregulatory Activity in Mice with Non-Tuberculosis Mycobacterial Lung Disease.Chinese journal of integrative medicine · 2026Article
- Preclinical pharmacokinetics/pharmacodynamics studies defining the role of ethambutol inAntimicrobial agents and chemotherapy · 2026Article
- Untargeted and Targeted Liquid Chromatography-Mass Spectrometry-Based Lipidomic Profiling Revealed a Potential Biomarker Panel to Distinguish Clinical Isolates of M. tuberculosis From Nontuberculous M. kansasii.Pulmonary medicine · 2026Article
- Analytical validation of a multiplex PCR assay for differentiation of five clinically significant nontuberculous mycobacterial species.Frontiers in microbiology · 2026Article
- Review of the Canadian Nontuberculous Mycobacterial Disease Landscape-Challenges and Opportunities.Tropical medicine and infectious disease · 2025Review
- Genomic-based genotype and drug susceptibility profile ofFrontiers in microbiology · 2025Article
- Efficacy and treatment outcome of infected patients with pulmonaryJournal of clinical tuberculosis and other mycobacterial diseases · 2024Review
- Phylogeographic Analysis of Mycobacterium kansasii Isolates from Patients with M. kansasii Lung Disease in Industrialized City, Taiwan.Emerging infectious diseases · 2024Article
- Phylogenomic and genomic analysis reveals unique and shared genetic signatures ofMicrobial genomics · 2024Article
- Detection of Mtb and NTM: preclinical validation of a new asymmetric PCR-binary deoxyribozyme sensor assay.Microbiology spectrum · 2024Article
- Molecular Characterisation ofPathogens (Basel, Switzerland) · 2023Article
- Case report: Intraabdominal infection ofFrontiers in medicine · 2023Article
- Treatment of non-tuberculosis mycobacteria skin infections.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycobacterium kansasii, an important opportunistic pathogen of humans, causes serious pulmonary disease. Sixty M. kansasii isolates were collected for investigating the clinical characteristics of patients with M. kansasii infections as well as drug susceptibility and genotypes of M. kansasii. More than 90% of the patients infected with M. kansasii were from eastern China. According to the internal transcribed spacers (ITS),
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.